Efficacy of erzhu jiedu recipe on hepatitis B cirrhosis with hyperalphafetoproteinemia: A randomized, double-blind, placebo-controlled clinical trial.

BACKGROUND: Hepatitis B cirrhosis with hyperalphafetoproteinemia is the intermediate stage of liver cirrhosis progressing to hepatocellular carcinoma (HCC), there is no effective way to treat precancerous lesions of liver in modern medicine. In recent decades, clinical and experimental evidence shows that Chinese medicine (CM) has a certain beneficial effect on Hepatitis B Cirrhosis. Therefore, this trial aims to evaluate the efficacy and safety of a CM erzhu jiedu recipe (EZJDR) for the treatment of Hepatitis B Cirrhosis with Hyperalphafetoproteinemia. METHODS: We designed a randomized, double blind, placebo-controlled clinical trial. A total of 72 patients of Hepatitis B Cirrhosis with hyperalphafetoproteinemia were randomized in 2 parallel groups. Patients in the control group received placebo granules similar to the EZJDR. In the EZJDR group, patients received EZJDR twice a day, after meals, for 48 weeks. The primary efficacy measures were changes in serum alpha-fetoprotein (AFP) and alpha-fetoprotein alloplasm (AFP-L3); The secondary indicators of efficacy are changes in liver function indicators, HBV-DNA level; Liver stiffness measurement (LSM); Hepatic portal vein diameter; T lymphocyte subgroup indexes during treatment. All data will be recorded in case report forms and analyzed by Statistical Analysis System software. Adverse events will also be evaluated. RESULTS: The results showed that EZJDR can significantly inhibit the levels of AFP and AFP-L3 in patients with hepatitis B cirrhosis and hyperalphafetoproteinemia and have good security. ETHICS AND DISSEMINATION: The study protocol was approved by the Medical Ethics Committee of Shuguang Hospital, affiliated with University of Traditional Chinese Medicine, Shanghai (NO.2018-579-08-01). TRIAL REGISTRATION: This trial was registered on Chinese Clinical Trial Center (NO.ChiCTR1800017165).

Studies on the growth, chemical components and physiological characteristics of F1 generation of Dendrobium huoshanense / 中国中药杂志

<p><b>OBJECTIVE</b>Through a comparison between F1 and its' parents on the growth, chemical components and physiology, this study aims to find the possibility of selecting new dendrobium hybrids with high yield and good quality.</p><p><b>METHOD</b>To determinate the growth, chemical components, photosynthesis, hormones and isoenzyme in the plants.</p><p><b>RESULT</b>Photosynthetic area, content of chlorophyll, net photosynthesis and yield of F1 generation are higher than those of the parents; chla/b rate is lower; growth is almost the same as in Dendrobium moniliforme; content of chemical components are the same as in D. huoshanense. F1 is approaching of advantages of parents.</p><p><b>CONCLUSION</b>Physiological characters, yield and quality of F1 are greatly improved by hybridization.</p>

[Study on glucose metabolic rate in non-small cell lung cancer patients with blood stasis syndrome and non-blood stasis syndrome].

OBJECTIVE: To study the difference of glucose metabolic rate in non-small cell lung cancer (NSCLC) patients with blood stasis syndrome and with non-blood stasis syndrome. METHODS: Whole body positron emission tomography (PET) and functional agent 2-[fluorine-18] fluorine-2-deoxy-glucose (18FDG) were used to detect the 18FDG uptake value in regions of interest (ROI) in tumor tissue of patients. RESULTS: In patients with same pathologic type, the maximum and mean standardized uptake value (Max SUV and Mean SUV) were significantly higher in the blood stasis group than those in the non-blood stasis group (P < 0.01); it also showed the same in patients with NSCLC of phase I, II and III (P < 0.05), but the 18FDG uptake rate was obviously enhanced in patients of phase IV (P < 0.01). CONCLUSION: The glucose uptake in NSCLC patients of blood stasis syndrome was higher than that in those with of non-blood stasis syndrome.